|
General Information
|
|
|
Product
|
CD19 Antibody BIOTIN-Conjugated
|
|
Description
|
BIOTIN-Conjugated B-lymphocyte antigen CD19 Antibody
|
|
Verified Applications
|
ELISA, WB
|
|
Host
|
Rabbit
|
|
Species Cross Reactivity
|
Human, Mouse, Rat
|
|
Immunogen
|
Synthetic peptide taken within amino acid region 200-250 on human CD19 protein.
|
|
Accession #
|
NCBI: AAB60697
|
|
Physical Properties
|
|
|
Quantity
|
100 µg
|
|
Volume
|
200 µl
|
|
Concentration
|
0.55-0.75 µg/µl in antibody stabilization buffer
|
|
Form
|
BIOTIN-Conjugated
|
|
Clonality
|
Polyclonal
|
|
Storage
|
-20⁰C for long term storage
|
|
Application Protocol
|
|
|
DB
|
1:10,000
|
|
ELISA
|
1:10,000
|
|
Western Blot
|
1:500
|
|
Protein
|
|
|
Uniprot #
|
P15391
|
|
Overview
|
Assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor dependent stimulation
|
|
Molecular Function
|
Receptor Signaling protein activity
|
|
Subcellular Location
|
Membrane; Single-pass type I membrane protein.
|
|
Structure
|
Contains 2 Ig-like C2-type domains.
|
|
Alternative Nomenclature
|
Antibody deficiency due to defect in CD19, included antibody
AW495831 antibody
CVID3 antibody
Leu 12 antibody
Lymphocyte Surface Antigen antibody
T-cell surface antigen Leu-12 antibody
|
CD19 Blocking Peptide
CD19 Antibody
CD19 Antibody FITC
CD19 Positive Control
